---
document_datetime: 2025-12-02 05:42:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/avonex.html
document_name: avonex.html
version: success
processing_time: 0.1127465
conversion_datetime: 2025-12-27 13:13:23.740995
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Avonex

[RSS](/en/individual-human-medicine.xml/66945)

##### Authorised

This medicine is authorised for use in the European Union

interferon beta-1a Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Avonex](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Avonex is a medicine used to treat:

- patients with relapsing multiple sclerosis (MS). MS is a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. In relapsing MS, the patient has attacks (relapses) between periods with no symptoms. Avonex slows the progression of disability and reduces the number of relapses;
- patients who have had a single attack of demyelination, when this is severe enough to need treatment with injectable corticosteroids (anti-inflammatory medicines). It is used when the patient is considered to be at high risk of developing MS. Before using Avonex, doctors need to exclude other causes for the symptoms.

Avonex contains the active substance interferon beta-1a.

Expand section

Collapse section

## How is Avonex used?

Avonex can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of MS.

Avonex is available as a solution for injection in a pre?filled syringe or pre?filled pen. Each syringe and pen contains 30 micrograms of interferon beta?1a.

In adults (aged 18 years or over), the recommended dose of Avonex is 30 micrograms, given by injection into a muscle once a week. To help patients adjust to treatment, the doctor may recommend that patients start with a lower dose once a week before increasing to the full dose. This can only be done with the pre?filled syringe, when it is fitted with a special device that attaches onto the syringe and only allows the lower dose of Avonex to be injected.

The site of injection should be changed each week. Patients can inject Avonex themselves once they have been trained. A painkiller that prevents fever can be given before each injection and for 24 hours after injection to reduce the flu-like symptoms that may occur during the first few months of treatment. Avonex treatment should be stopped in patients who develop progressive (worsening) MS.

For more information about using Avonex, see the package leaflet or contact your doctor or pharmacist.

## How does Avonex work?

The active substance in Avonex is the protein interferon beta-1a, one of a group of interferons that can be naturally produced by the body to help it fight against viruses and other attacks. In MS, the immune system (the body's natural defences) malfunctions and attacks parts of the central nervous system (the brain, spinal cord and optic nerve [nerve that sends signals from the eye to the brain]), causing inflammation that damages the nerves and the insulation around them. The exact way that Avonex works in MS is not yet known but the active substance, interferon beta-1a, seems to calm down the immune system, and prevents relapses of MS.

## What benefits of Avonex have been shown in studies?

Avonex has been compared with placebo (a dummy treatment) in two main studies. The first study involved 301 patients aged 16 years and older with relapsing MS who had experienced at least two relapses in the previous three years or at least one relapse per year if they had had the disease for less than three years. Treatment continued for up to two years. The main measure of effectiveness was the number of patients whose disability got worse. After two years, 22% of the patients who were treated with Avonex and 35% of the patients treated with placebo had a worsening of disability.

The second study involved 383 adults who had experienced a single attack of demyelination and compared the ability of Avonex and placebo to reduce the risk of a second attack. The estimated risk of having a second attack of demyelination was lower in the patients taking Avonex than in the patients taking placebo: with Avonex, the risk was 21% in two years and 35% in three years, whereas the risk with placebo was 39% in two years and 50% in three years.

The company has not carried out any formal studies of patients under 16 years of age. However, it presented information from published studies on the use of Avonex in patients aged between 12 and 18 years, which showed that they had a decrease in the rate of relapse, possibly due to Avonex treatment.

## What are the risks associated with Avonex?

The most common side effects with Avonex (which may affect more than 1 in 10 people) are headache, flu-like symptoms, pyrexia (fever), chills and sweating. These side effects decrease with continued treatment. The side effects are similar in adults and in children.

Avonex must not be used in patients who have severe depression or have thoughts of suicide.

For the full list of side effects and restrictions with Avonex, see the package leaflet.

## Why is Avonex authorised in the EU?

The European Medicines Agency decided that Avonex's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Avonex?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Avonex have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Avonex are continuously monitored. Side effects reported with Avonex are carefully evaluated and any necessary action taken to protect patients.

## Other information about Avonex

Avonex received a marketing authorisation valid throughout the EU on 13 March 1997.

Avonex : EPAR - Medicine overview

Reference Number: EMA/685524/2019

English (EN) (146.58 KB - PDF)

**First published:** 19/03/2009

**Last updated:** 19/12/2019

[View](/en/documents/overview/avonex-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-166)

български (BG) (170.42 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/bg/documents/overview/avonex-epar-medicine-overview_bg.pdf)

español (ES) (175.27 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/es/documents/overview/avonex-epar-medicine-overview_es.pdf)

čeština (CS) (170.12 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/cs/documents/overview/avonex-epar-medicine-overview_cs.pdf)

dansk (DA) (145.43 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/da/documents/overview/avonex-epar-medicine-overview_da.pdf)

Deutsch (DE) (149.1 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/de/documents/overview/avonex-epar-medicine-overview_de.pdf)

eesti keel (ET) (142.46 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/et/documents/overview/avonex-epar-medicine-overview_et.pdf)

ελληνικά (EL) (175.32 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/el/documents/overview/avonex-epar-medicine-overview_el.pdf)

français (FR) (147.68 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/fr/documents/overview/avonex-epar-medicine-overview_fr.pdf)

hrvatski (HR) (170 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/hr/documents/overview/avonex-epar-medicine-overview_hr.pdf)

italiano (IT) (145.22 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/it/documents/overview/avonex-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (184.95 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/lv/documents/overview/avonex-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (170.01 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/lt/documents/overview/avonex-epar-medicine-overview_lt.pdf)

magyar (HU) (168.62 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/hu/documents/overview/avonex-epar-medicine-overview_hu.pdf)

Malti (MT) (171.19 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/mt/documents/overview/avonex-epar-medicine-overview_mt.pdf)

Nederlands (NL) (145.56 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/nl/documents/overview/avonex-epar-medicine-overview_nl.pdf)

polski (PL) (171.47 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/pl/documents/overview/avonex-epar-medicine-overview_pl.pdf)

português (PT) (146.93 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/pt/documents/overview/avonex-epar-medicine-overview_pt.pdf)

română (RO) (167.18 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/ro/documents/overview/avonex-epar-medicine-overview_ro.pdf)

slovenčina (SK) (169.6 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/sk/documents/overview/avonex-epar-medicine-overview_sk.pdf)

slovenščina (SL) (167.75 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/sl/documents/overview/avonex-epar-medicine-overview_sl.pdf)

Suomi (FI) (144.82 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/fi/documents/overview/avonex-epar-medicine-overview_fi.pdf)

svenska (SV) (144.89 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/12/2019

[View](/sv/documents/overview/avonex-epar-medicine-overview_sv.pdf)

## Product information

Avonex : EPAR - Product Information

English (EN) (706.86 KB - PDF)

**First published:** 19/03/2009

**Last updated:** 16/10/2025

[View](/en/documents/product-information/avonex-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-877)

български (BG) (870.77 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/bg/documents/product-information/avonex-epar-product-information_bg.pdf)

español (ES) (773.07 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/es/documents/product-information/avonex-epar-product-information_es.pdf)

čeština (CS) (820.71 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/cs/documents/product-information/avonex-epar-product-information_cs.pdf)

dansk (DA) (727.83 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/da/documents/product-information/avonex-epar-product-information_da.pdf)

Deutsch (DE) (790.79 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/de/documents/product-information/avonex-epar-product-information_de.pdf)

eesti keel (ET) (780.75 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/et/documents/product-information/avonex-epar-product-information_et.pdf)

ελληνικά (EL) (839.96 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/el/documents/product-information/avonex-epar-product-information_el.pdf)

français (FR) (824.18 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/fr/documents/product-information/avonex-epar-product-information_fr.pdf)

hrvatski (HR) (812.02 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/hr/documents/product-information/avonex-epar-product-information_hr.pdf)

íslenska (IS) (833.75 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/is/documents/product-information/avonex-epar-product-information_is.pdf)

italiano (IT) (762.89 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/it/documents/product-information/avonex-epar-product-information_it.pdf)

latviešu valoda (LV) (825.34 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/lv/documents/product-information/avonex-epar-product-information_lv.pdf)

lietuvių kalba (LT) (964.18 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/lt/documents/product-information/avonex-epar-product-information_lt.pdf)

magyar (HU) (815.26 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/hu/documents/product-information/avonex-epar-product-information_hu.pdf)

Malti (MT) (897.38 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/mt/documents/product-information/avonex-epar-product-information_mt.pdf)

Nederlands (NL) (792.47 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/nl/documents/product-information/avonex-epar-product-information_nl.pdf)

norsk (NO) (745.6 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/no/documents/product-information/avonex-epar-product-information_no.pdf)

polski (PL) (916.17 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/pl/documents/product-information/avonex-epar-product-information_pl.pdf)

português (PT) (750.73 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/pt/documents/product-information/avonex-epar-product-information_pt.pdf)

română (RO) (763.29 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/ro/documents/product-information/avonex-epar-product-information_ro.pdf)

slovenčina (SK) (832.48 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/sk/documents/product-information/avonex-epar-product-information_sk.pdf)

slovenščina (SL) (792.85 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/sl/documents/product-information/avonex-epar-product-information_sl.pdf)

Suomi (FI) (759.49 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/fi/documents/product-information/avonex-epar-product-information_fi.pdf)

svenska (SV) (718.82 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

16/10/2025

[View](/sv/documents/product-information/avonex-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000300515 16/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Avonex : EPAR - All Authorised presentations

English (EN) (20.14 KB - PDF)

**First published:** 29/08/2007

**Last updated:** 24/07/2019

[View](/en/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-991)

български (BG) (47.84 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/bg/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_bg.pdf)

español (ES) (22.52 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/es/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_es.pdf)

čeština (CS) (46.07 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/cs/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.94 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/da/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (16.33 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/de/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (58.86 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/et/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.8 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/el/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_el.pdf)

français (FR) (16.83 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/fr/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (47.38 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/hr/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (21.97 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/is/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.18 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/it/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (41.78 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/lv/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (40.96 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/lt/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (41.93 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/hu/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (67.11 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/mt/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (23.45 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/nl/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (24.51 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/no/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_no.pdf)

polski (PL) (48.76 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/pl/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.6 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/pt/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_pt.pdf)

română (RO) (43.08 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/ro/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (42.15 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/sk/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (32.57 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/sl/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (22.69 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/fi/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.65 KB - PDF)

**First published:**

29/08/2007

**Last updated:**

24/07/2019

[View](/sv/documents/all-authorised-presentations/avonex-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Avonex Active substance interferon beta-1a International non-proprietary name (INN) or common name interferon beta-1a Therapeutic area (MeSH) Multiple Sclerosis Anatomical therapeutic chemical (ATC) code L03AB07

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

Avonex is indicated for the treatment of:

- patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; Avonex slows the progression of disability and decreases the frequency of relapses;
- patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite MS.

Avonex should be discontinued in patients who develop progressive MS.

## Authorisation details

EMA product number EMEA/H/C/000102 Marketing authorisation holder

Biogen Netherlands B.V.

Prins Mauritslaan 13 1171 LP Badhoevedorp The Netherlands

Marketing authorisation issued 13/03/1997 Revision 40

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Avonex : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (244.95 KB - PDF)

**First published:** 16/10/2025

[View](/en/documents/procedural-steps-after/avonex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Avonex : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (325.61 KB - PDF)

**First published:** 19/03/2009

**Last updated:** 16/10/2025

[View](/en/documents/procedural-steps-after/avonex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Avonex-PAM-0000245472 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMADOC-1700519818-1850245

English (EN) (452.39 KB - PDF)

**First published:** 10/04/2025

[View](/en/documents/variation-report/avonex-pam-0000245472-epar-assessment-report-variation_en.pdf)

Avonex-H-C-102-II-0193 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/23616/2023

English (EN) (603.39 KB - PDF)

**First published:** 18/01/2023

[View](/en/documents/variation-report/avonex-h-c-102-ii-0193-epar-assessment-report-variation_en.pdf-0)

Avonex-H-C-102-II-0108 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/374288/2011

English (EN) (117.56 KB - PDF)

**First published:** 07/02/2013

**Last updated:** 07/02/2013

[View](/en/documents/variation-report/avonex-h-c-102-ii-0108-epar-assessment-report-variation_en.pdf)

Avonex : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (103.2 KB - PDF)

**First published:** 16/08/2006

**Last updated:** 16/08/2006

[View](/en/documents/steps-after-cutoff/avonex-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Avonex : EPAR - Scientific Discussion

English (EN) (316.31 KB - PDF)

**First published:** 16/08/2006

**Last updated:** 16/08/2006

[View](/en/documents/scientific-discussion/avonex-epar-scientific-discussion_en.pdf)

Avonex : EPAR - Procedural steps taken before authorisation

English (EN) (97.55 KB - PDF)

**First published:** 16/08/2006

**Last updated:** 16/08/2006

[View](/en/documents/procedural-steps/avonex-epar-procedural-steps-taken-authorisation_en.pdf)

#### More information on Avonex

- [Non-interventional Safety Study to Investigate Pregnancy Outcomes in Female Patients Exposed to SC Peginterferon Beta-1a and IM Interferon Beta-1a Reported in a German Patient Support Program - post-authorisation study](https://catalogues.ema.europa.eu/study/49260)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 16/10/2025

## Share this page

[Back to top](#main-content)